首页 › 基金 › Novo Holdings A/S › COAG

Novo Holdings A/S 对 COAG 的持仓历史

HEMAB THERAPEUTICS HLDGS INC · 医疗保健

Novo Holdings A/S 在 Q3 2026 的 13F 申报中披露持有 COAG(HEMAB THERAPEUTICS HLDGS INC)4,180,550 股,市值约 US$128.9M,约占其申报组合的 8.65%,在其申报持仓中市值排名第 4 位。 Novo Holdings A/S 最近 2 个申报季度中有 2 个季度披露了 COAG 持仓,最早可追溯至 Q2 2026。

最新持仓 (Q3 2026)4.18M 股
申报持仓市值$128.93M
组合权重8.65%
首次申报Q2 2026
最近变动持有
更新于2026-11-17

最后更新: 2026-11-17 · 来源: SEC EDGAR Form 13F-HR

Novo Holdings A/S 对 COAG 的持仓演变

Novo Holdings A/S 于 Q2 2026 首次披露 COAG 持仓:4,180,550 股(约 US$153.6M)。 在 2 次申报中,Novo Holdings A/S 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 4,180,550 股、市值约 US$128.9M。

逐季持仓明细

季度股数金额变化
Q2 2026 4.18M $153.55M 新进
Q3 2026 4.18M $128.93M 持有

折线上的点按变动类型着色;缺失季度表示该季未申报持仓。

关于 COAG 与 13F 数据

COAG(HEMAB THERAPEUTICS HLDGS INC)属于医疗保健行业。我们追踪的基金中还有 90 只申报持有 COAG,申报仓位最大的包括:RA CAPITAL MANAGEMENT, L.P. (US$240.8M), Deep Track Capital, LP (US$110.6M), Siren, L.L.C. (US$73.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。

其它持有 COAG 的基金

查看 COAG 的全部基金持有人 →

常见问题

How long has Novo Holdings A/S held COAG?

Novo Holdings A/S has disclosed COAG holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is Novo Holdings A/S's current position in COAG?

As of Q3 2026, Novo Holdings A/S holds 4.18M shares of COAG (HEMAB THERAPEUTICS HLDGS INC), valued at $128.93M, representing 8.65% of its reported portfolio and ranking #4.

Has Novo Holdings A/S been buying or selling COAG?

In the latest 13F filing (Q3 2026), Novo Holdings A/S held unchanged its position in COAG.

Which other funds hold COAG?

Other major institutional holders of COAG include RA CAPITAL MANAGEMENT, L.P., Deep Track Capital, LP, Siren, L.L.C., among 90 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.